Clinical Guidance Paper VVOG: Pharmacological treatment of endometriosis-related pain

Ellen Remans, Richard P. Ellen, Remans E, Céline Bafort, Bafort C, Celine Bafort, Celine Blank, Blank C, Alex Bongima, Bongima A, Brecht Geysenbergh, Tjalina Hamerlynck, Hamerlynck T, Page G, Geert Page, Verguts J, Jasper Verguts, Carla Tomassetti
European journal of obstetrics & gynecology and reproductive biology: X · 2025 · vol. 27 , pp. 100403 · doi:10.1016/j.eurox.2025.100403 · PMID:40740165 · PMC12309268 · W4410894033
article OA: gold CC0
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This clinical guidance paper provides recommendations for the pharmacological management of endometriosis-associated pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-04 · read from full text ⓘ

This VVOG clinical guidance paper addresses pharmacological treatment options for endometriosis-related pain, drawing on available evidence to outline how drug therapies are used in clinical practice. It discusses the main pharmacological classes relevant to symptom control while emphasizing considerations that influence therapeutic choice. The authors explicitly state that competing financial interests among some contributors were present but reported as having no impact on the guidance’s development. This paper is centrally about endometriosis-related pain — it provides clinical guidance on pharmacological treatment of endometriosis-related symptoms.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Gedeon Richter and Ferring Pharmaceuticals; Gedeon-Richter; Samsung
Full text 2,361 characters · extracted from pmc-nxml · 1 sections · click to expand

Coi Statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Celine Bafort, gynecologist, UZ Leuven: Received sponsorship by Gedeon Richter and Ferring Pharmaceuticals to travel and attend scientific meetings Dr. Celine Blank: Received sponsorship from Gedeon-Richter, Bridea, Erbe, Goodlife, Memidis Pharma B.v., Ferring Pharmaceuticals and Samsung healthcare Dr. Brecht Geysenbergh - Member advisory board Gedeon-Richter - Received sponsorship from Gedeon-Richter, Theramex, Merck, Ferring and Goodlife Member advisory board Gedeon-Richter Received sponsorship from Gedeon-Richter, Theramex, Merck, Ferring and Goodlife Dr. Jasper Verguts, gynecologist, Jessa Hospital Hasselt: - Member national and international advisory board Gedeon Richter - Received sponsorship form Theramex and Merck. Member national and international advisory board Gedeon Richter Received sponsorship form Theramex and Merck. Prof. Dr. Carla Tomassetti, gynecologist, UZ Leuven: - Deputy director of JMIG (paid to institution, no private revenue) - Received sponsoring by Merck SA for a clinical fellowship programme for reproductive endocrinology (paid to institution, no private revenue), consulting fees from Gedeon Richter and Merck SA (paid to institution, no private revenue), honoraria for lectures/presentations by Gedeon Richter, Merck SA and Ferring Pharmaceutical (paid to institution, no private revenue), sponsoring by Gedeon Richter, Merck SA and Ferring to travel and attend scientific meetings. Deputy director of JMIG (paid to institution, no private revenue) Received sponsoring by Merck SA for a clinical fellowship programme for reproductive endocrinology (paid to institution, no private revenue), consulting fees from Gedeon Richter and Merck SA (paid to institution, no private revenue), honoraria for lectures/presentations by Gedeon Richter, Merck SA and Ferring Pharmaceutical (paid to institution, no private revenue), sponsoring by Gedeon Richter, Merck SA and Ferring to travel and attend scientific meetings. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. These conflicts of interest had no impact on the development of this clinical guidance.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (85)

Source provenance

europepmc
last seen: 2026-08-06T06:07:45.168820+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pmc
last seen: 2026-05-13T20:22:03.195721+00:00
pubmed
last seen: 2026-08-06T06:04:22.846102+00:00
License: CC0 · commercial use OK